{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:06:02Z","timestamp":1782489962721,"version":"3.54.5"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s10549-019-05359-w","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T10:02:37Z","timestamp":1563530557000},"page":"151-159","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Assessing the effectiveness of the National Comprehensive Cancer Network genetic testing guidelines in identifying African American breast cancer patients with deleterious genetic mutations"],"prefix":"10.1007","volume":"178","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6766-2258","authenticated-orcid":false,"given":"Foluso O.","family":"Ademuyiwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Salyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinjiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherri","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Colditz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Weilbaecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Bierut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,19]]},"reference":[{"issue":"4988","key":"5359_CR1","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1126\/science.2270482","volume":"250","author":"JM Hall","year":"1990","unstructured":"Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC (1990) Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250(4988):1684\u20131689","journal-title":"Science"},{"issue":"5182","key":"5359_CR2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1126\/science.7545954","volume":"266","author":"Y Miki","year":"1994","unstructured":"Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science (New York, NY) 266(5182):66\u201371","journal-title":"Science (New York, NY)"},{"issue":"18","key":"5359_CR3","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1001\/jama.286.18.2251","volume":"286","author":"MC King","year":"2001","unstructured":"King MC, Wieand S, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Dunn BK, Costantino J, Wickerham L, Wolmark N, Fisher B, National Surgical Adjuvant B, Bowel P (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286(18):2251\u20132256","journal-title":"JAMA"},{"issue":"2","key":"5359_CR4","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/sj.bjc.6600064","volume":"86","author":"SW Duffy","year":"2002","unstructured":"Duffy SW, Nixon RM (2002) Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations. Br J Cancer 86(2):218\u2013221. \n                    https:\/\/doi.org\/10.1038\/sj.bjc.6600064","journal-title":"Br J Cancer"},{"issue":"2","key":"5359_CR5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1093\/jnci\/djn442","volume":"101","author":"TR Rebbeck","year":"2009","unstructured":"Rebbeck TR, Kauff ND, Domchek SM (2009) Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 101(2):80\u201387. \n                    https:\/\/doi.org\/10.1093\/jnci\/djn442","journal-title":"J Natl Cancer Inst"},{"issue":"30","key":"5359_CR6","doi-asserted-by":"publisher","first-page":"7491","DOI":"10.1200\/JCO.2004.00.7138","volume":"23","author":"A Eisen","year":"2005","unstructured":"Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, Weber B, Rebbeck T, Neuhausen SL, Ghadirian P, Foulkes WD, Gershoni-Baruch R, Friedman E, Rennert G, Wagner T, Isaacs C, Kim-Sing C, Ainsworth P, Sun P, Narod SA (2005) Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 23(30):7491\u20137496. \n                    https:\/\/doi.org\/10.1200\/JCO.2004.00.7138","journal-title":"J Clin Oncol"},{"issue":"9","key":"5359_CR7","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1038\/bjc.2011.120","volume":"104","author":"K Metcalfe","year":"2011","unstructured":"Metcalfe K, Gershman S, Lynch HT, Ghadirian P, Tung N, Kim-Sing C, Olopade OI, Domchek S, McLennan J, Eisen A, Foulkes WD, Rosen B, Sun P, Narod SA (2011) Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Br J Cancer 104(9):1384\u20131392. \n                    https:\/\/doi.org\/10.1038\/bjc.2011.120","journal-title":"Br J Cancer"},{"issue":"3","key":"5359_CR8","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1001\/jamaoncol.2015.0658","volume":"1","author":"K Metcalfe","year":"2015","unstructured":"Metcalfe K, Lynch HT, Foulkes WD, Tung N, Kim-Sing C, Olopade OI, Eisen A, Rosen B, Snyder C, Gershman S, Sun P, Narod SA (2015) Effect of oophorectomy on survival after breast cancer in BRCA1 and BRCA2 mutation carriers. JAMA Oncol 1(3):306\u2013313. \n                    https:\/\/doi.org\/10.1001\/jamaoncol.2015.0658","journal-title":"JAMA Oncol"},{"issue":"1","key":"5359_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/jnci\/djw177","volume":"109","author":"J Kotsopoulos","year":"2017","unstructured":"Kotsopoulos J, Huzarski T, Gronwald J, Singer CF, Moller P, Lynch HT, Armel S, Karlan B, Foulkes WD, Neuhausen SL, Senter L, Tung N, Weitzel JN, Eisen A, Metcalfe K, Eng C, Pal T, Evans G, Sun P, Lubinski J, Narod SA, Hereditary Breast Cancer Clinical Study G (2017) Bilateral oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 109(1):89. \n                    https:\/\/doi.org\/10.1093\/jnci\/djw177","journal-title":"J Natl Cancer Inst"},{"issue":"11S","key":"5359_CR10","doi-asserted-by":"publisher","first-page":"S383","DOI":"10.1016\/j.jacr.2017.08.044","volume":"14","author":"MB Mainiero","year":"2017","unstructured":"Expert Panel on Breast I, Mainiero MB, Moy L, Baron P, Didwania AD, diFlorio RM, Green ED, Heller SL, Holbrook AI, Lee SJ, Lewin AA, Lourenco AP, Nance KJ, Niell BL, Slanetz PJ, Stuckey AR, Vincoff NS, Weinstein SP, Yepes MM, Newell MS (2017) ACR appropriateness criteria((R)) breast cancer screening. J Am Coll Radiol 14(11S):S383\u2013S390. \n                    https:\/\/doi.org\/10.1016\/j.jacr.2017.08.044","journal-title":"J Am Coll Radiol"},{"issue":"9","key":"5359_CR11","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1002\/cncr.20971","volume":"103","author":"CD Lehman","year":"2005","unstructured":"Lehman CD, Blume JD, Weatherall P, Thickman D, Hylton N, Warner E, Pisano E, Schnitt SJ, Gatsonis C, Schnall M, DeAngelis GA, Stomper P, Rosen EL, O\u2019Loughlin M, Harms S, Bluemke DA, International Breast MRICWG (2005) Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer 103(9):1898\u20131905. \n                    https:\/\/doi.org\/10.1002\/cncr.20971","journal-title":"Cancer"},{"issue":"33","key":"5359_CR12","doi-asserted-by":"publisher","first-page":"8469","DOI":"10.1200\/JCO.2004.00.4960","volume":"23","author":"CK Kuhl","year":"2005","unstructured":"Kuhl CK, Schrading S, Leutner CC, Morakkabati-Spitz N, Wardelmann E, Fimmers R, Kuhn W, Schild HH (2005) Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol 23(33):8469\u20138476. \n                    https:\/\/doi.org\/10.1200\/JCO.2004.00.4960","journal-title":"J Clin Oncol"},{"issue":"11","key":"5359_CR13","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jama.292.11.1317","volume":"292","author":"E Warner","year":"2004","unstructured":"Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, Cutrara MR, DeBoer G, Yaffe MJ, Messner SJ, Meschino WS, Piron CA, Narod SA (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292(11):1317\u20131325. \n                    https:\/\/doi.org\/10.1001\/jama.292.11.1317","journal-title":"JAMA"},{"issue":"9473","key":"5359_CR14","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/S0140-6736(05)66481-1","volume":"365","author":"MO Leach","year":"2005","unstructured":"Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, Gilbert FJ, Griebsch I, Hoff RJ, Kessar P, Lakhani SR, Moss SM, Nerurkar A, Padhani AR, Pointon LJ, Thompson D, Warren RM, group Ms (2005) Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 365(9473):1769\u20131778. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(05)66481-1","journal-title":"Lancet"},{"issue":"8","key":"5359_CR15","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J, Hurvitz SA, Goncalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roche H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL (2018) Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 379(8):753\u2013763. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1802905","journal-title":"N Engl J Med"},{"issue":"6","key":"5359_CR16","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377(6):523\u2013533. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1706450","journal-title":"N Engl J Med"},{"issue":"7355","key":"5359_CR17","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/475163a","volume":"475","author":"CD Bustamante","year":"2011","unstructured":"Bustamante CD, Burchard EG, De la Vega FM (2011) Genomics for the world. Nature 475(7355):163\u2013165. \n                    https:\/\/doi.org\/10.1038\/475163a","journal-title":"Nature"},{"issue":"7125","key":"5359_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/445259a","volume":"445","author":"FS Collins","year":"2007","unstructured":"Collins FS, Manolio TA (2007) Merging and emerging cohorts: necessary but not sufficient. Nature 445(7125):259. \n                    https:\/\/doi.org\/10.1038\/445259a","journal-title":"Nature"},{"issue":"11","key":"5359_CR19","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.tig.2009.09.012","volume":"25","author":"AC Need","year":"2009","unstructured":"Need AC, Goldstein DB (2009) Next generation disparities in human genomics: concerns and remedies. Trends Genet 25(11):489\u2013494. \n                    https:\/\/doi.org\/10.1016\/j.tig.2009.09.012","journal-title":"Trends Genet"},{"issue":"4","key":"5359_CR20","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1159\/000116878","volume":"11","author":"RD James","year":"2008","unstructured":"James RD, Yu JH, Henrikson NB, Bowen DJ, Fullerton SM, Health Disparities Working G (2008) Strategies and stakeholders: minority recruitment in cancer genetics research. Community Genet 11(4):241\u2013249. \n                    https:\/\/doi.org\/10.1159\/000116878","journal-title":"Community Genet"},{"issue":"21","key":"5359_CR21","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","volume":"295","author":"LA Carey","year":"2006","unstructured":"Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492\u20132502. \n                    https:\/\/doi.org\/10.1001\/jama.295.21.2492","journal-title":"JAMA"},{"issue":"3","key":"5359_CR22","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s10549-010-1191-6","volume":"127","author":"SL Ooi","year":"2011","unstructured":"Ooi SL, Martinez ME, Li CI (2011) Disparities in breast cancer characteristics and outcomes by race\/ethnicity. Breast Cancer Res Treat 127(3):729\u2013738. \n                    https:\/\/doi.org\/10.1007\/s10549-010-1191-6","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"5359_CR23","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3322\/caac.21412","volume":"67","author":"CE DeSantis","year":"2017","unstructured":"DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A (2017) Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin 67(6):439\u2013448. \n                    https:\/\/doi.org\/10.3322\/caac.21412","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"5359_CR24","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1002\/cncr.29178","volume":"121","author":"FO Ademuyiwa","year":"2015","unstructured":"Ademuyiwa FO, Gao F, Hao L, Morgensztern D, Aft RL, Ma CX, Ellis MJ (2015) US breast cancer mortality trends in young women according to race. Cancer 121(9):1469\u20131476. \n                    https:\/\/doi.org\/10.1002\/cncr.29178","journal-title":"Cancer"},{"issue":"14","key":"5359_CR25","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/jama.293.14.1729","volume":"293","author":"K Armstrong","year":"2005","unstructured":"Armstrong K, Micco E, Carney A, Stopfer J, Putt M (2005) Racial differences in the use of BRCA1\/2 testing among women with a family history of breast or ovarian cancer. JAMA 293(14):1729\u20131736. \n                    https:\/\/doi.org\/10.1001\/jama.293.14.1729","journal-title":"JAMA"},{"issue":"1","key":"5359_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10549-014-3195-0","volume":"149","author":"JE Churpek","year":"2015","unstructured":"Churpek JE, Walsh T, Zheng Y, Moton Z, Thornton AM, Lee MK, Casadei S, Watts A, Neistadt B, Churpek MM, Huo D, Zvosec C, Liu F, Niu Q, Marquez R, Zhang J, Fackenthal J, King MC, Olopade OI (2015) Inherited predisposition to breast cancer among African American women. Breast Cancer Res Treat 149(1):31\u201339. \n                    https:\/\/doi.org\/10.1007\/s10549-014-3195-0","journal-title":"Breast Cancer Res Treat"},{"key":"5359_CR27","unstructured":"States SCotU (2013) Association for molecular pathology et al. v. Myriad Genetics, inc., et al.. vol 12-398"},{"issue":"1","key":"5359_CR28","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1214\/aoms\/1177705148","volume":"32","author":"LA Goodman","year":"1961","unstructured":"Goodman LA (1961) Snowball sampling. Ann Math Stat 32(1):148\u2013170","journal-title":"Ann Math Stat"},{"issue":"2","key":"5359_CR29","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/tbj.12083","volume":"19","author":"T Pal","year":"2013","unstructured":"Pal T, Bonner D, Kim J, Monteiro AN, Kessler L, Royer R, Narod SA, Vadaparampil ST (2013) Early onset breast cancer in a registry-based sample of African-american women: BRCA mutation prevalence, and other personal and system-level clinical characteristics. Breast J 19(2):189\u2013192. \n                    https:\/\/doi.org\/10.1111\/tbj.12083","journal-title":"Breast J"},{"issue":"15_suppl","key":"5359_CR30","doi-asserted-by":"publisher","first-page":"e13624","DOI":"10.1200\/jco.2018.36.15_suppl.e13624","volume":"36","author":"NM Tung","year":"2018","unstructured":"Tung NM, Bobbili PJ, Olufade TO, DerSarkissian M, Bhak R, Reiff J, Briceno JM, Yu H, Shenolikar R, Duh MS (2018) Adherence to National Comprehensive Cancer Network Guidelines for BRCA testing among breast cancer patients. J Clin Oncol 36(15_suppl):e13624\u2013e13624. \n                    https:\/\/doi.org\/10.1200\/jco.2018.36.15_suppl.e13624","journal-title":"J Clin Oncol"},{"issue":"5","key":"5359_CR31","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1086\/375033","volume":"72","author":"A Antoniou","year":"2003","unstructured":"Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles DM, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallioniemi OP, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117\u20131130. \n                    https:\/\/doi.org\/10.1086\/375033","journal-title":"Am J Hum Genet"},{"issue":"1","key":"5359_CR32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/ng853","volume":"31","author":"PD Pharoah","year":"2002","unstructured":"Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA (2002) Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 31(1):33\u201336. \n                    https:\/\/doi.org\/10.1038\/ng853","journal-title":"Nat Genet"},{"issue":"3","key":"5359_CR33","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1086\/301749","volume":"62","author":"D Ford","year":"1998","unstructured":"Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62(3):676\u2013689. \n                    https:\/\/doi.org\/10.1086\/301749","journal-title":"Am J Hum Genet"},{"issue":"6","key":"5359_CR34","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1200\/JCO.2002.20.6.1480","volume":"20","author":"TS Frank","year":"2002","unstructured":"Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, Critchfield GC (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20(6):1480\u20131490. \n                    https:\/\/doi.org\/10.1200\/JCO.2002.20.6.1480","journal-title":"J Clin Oncol"},{"issue":"11","key":"5359_CR35","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1001\/jama.2014.12483","volume":"312","author":"MC King","year":"2014","unstructured":"King MC, Levy-Lahad E, Lahad A (2014) Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. JAMA 312(11):1091\u20131092. \n                    https:\/\/doi.org\/10.1001\/jama.2014.12483","journal-title":"JAMA"},{"issue":"6","key":"5359_CR36","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/JCO.18.01631","volume":"37","author":"PD Beitsch","year":"2019","unstructured":"Beitsch PD, Whitworth PW, Hughes K, Patel R, Rosen B, Compagnoni G, Baron P, Simmons R, Smith LA, Grady I, Kinney M, Coomer C, Barbosa K, Holmes DR, Brown E, Gold L, Clark P, Riley L, Lyons S, Ruiz A, Kahn S, MacDonald H, Curcio L, Hardwick MK, Yang S, Esplin ED, Nussbaum RL (2019) Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol 37(6):453\u2013460. \n                    https:\/\/doi.org\/10.1200\/JCO.18.01631","journal-title":"J Clin Oncol"},{"key":"5359_CR37","unstructured":"Surgeons ASoB American Society of Breast Surgeons. \n                    https:\/\/www.breastsurgeons.org\/about\/statements\/PDF_Statements\/Hereditary_Genetic_Testing_Patients_With_Without_Breast_Cancer.pdf\n                    \n                  . Accessed 24 May 2019"},{"issue":"15","key":"5359_CR38","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1001\/jama.294.15.1925","volume":"294","author":"R Nanda","year":"2005","unstructured":"Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F, Cobleigh M, Esserman L, Lindor NM, Neuhausen SL, Olopade OI (2005) Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA 294(15):1925\u20131933. \n                    https:\/\/doi.org\/10.1001\/jama.294.15.1925","journal-title":"JAMA"},{"issue":"12","key":"5359_CR39","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/nrc2054","volume":"7","author":"JD Fackenthal","year":"2007","unstructured":"Fackenthal JD, Olopade OI (2007) Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 7(12):937\u2013948. \n                    https:\/\/doi.org\/10.1038\/nrc2054","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"5359_CR40","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1001\/jama.279.12.915","volume":"279","author":"B Newman","year":"1998","unstructured":"Newman B, Mu H, Butler LM, Millikan RC, Moorman PG, King MC (1998) Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 279(12):915\u2013921","journal-title":"JAMA"},{"issue":"10","key":"5359_CR41","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1093\/annonc\/mdp051","volume":"20","author":"BG Haffty","year":"2009","unstructured":"Haffty BG, Choi DH, Goyal S, Silber A, Ranieri K, Matloff E, Lee MH, Nissenblatt M, Toppmeyer D, Moran MS (2009) Breast cancer in young women (YBC): prevalence of BRCA1\/2 mutations and risk of secondary malignancies across diverse racial groups. Ann Oncol 20(10):1653\u20131659. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdp051","journal-title":"Ann Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05359-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-019-05359-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05359-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T23:15:34Z","timestamp":1595027734000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-019-05359-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,19]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["5359"],"URL":"https:\/\/doi.org\/10.1007\/s10549-019-05359-w","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,19]]},"assertion":[{"value":"17 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Foluso Ademuyiwa has served as an advisory board member for Eisai, Astra Zeneca, Jounce, Immunomedics, and QED Therapeutics. Foluso Ademuyiwa performs consulting for Cardinal Health, Best Doctors, Advance Medical Inc. Foluso Ademuyiwa has received institutional research funding from Polyphor, Pfizer, RNA Diagnostics, Immunomedics, Abbvie, and Seattle Genetics. Laura J. Bierut is listed as an inventor on Issued U.S. Patent 8,080,371,\u201cMarkers for Addiction\u201d covering the use of certain SNPs in determining the diagnosis, prognosis, and treatment of addiction. Patricia Salyer, Yinjiao Ma, Sherri Fisher, Graham Colditz, and Katherine Weilbaecher declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with animals performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}